Enlivex <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Positive Phase IIa Allocetra Results in Knee Osteoarthritis
Enlivex Therapeutics Ltd. has announced that it will present new clinical data from its Phase IIa trial evaluating Allocetra™ in patients with moderate-to-severe knee osteoarthritis at the American College of Rheumatology $(ACR)$ Convergence 2025, scheduled for October 24-29 in Chicago, Illinois. The late-breaking poster presentation will feature 3-month topline data from the ENX-CL-05-001 study, reporting clinically meaningful and statistically significant improvements in pain reduction and functional outcomes compared to placebo in idiopathic age-related osteoarthritis patients aged 60 and above. The presentation will also include new biomarker data and findings regarding responder populations. Results will be presented by Professor Philip Conaghan on October 28, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enlivex Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9563395-en) on October 28, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。